Exelixis - EXEL Market Capitalization

Exelixis, Inc. (EXEL) dominates the treatment of renal tumors, expanding the application spectrum of its agents to protect market share. Strong patent protection and consistent demand transform flagship products into high-profit generators, while the market capitalization stands at 17.29. This price chart on GURU.Markets complements the picture of a business that utilizes outsourcing for production and trials to concentrate on innovation.

EXEL Exelixis: Market Value in the range 07/04/2022 - 11/12/2026

Exelixis Inc. - analytical breakdowns and key metrics (EXEL)

- stock price and consensus target price:

Stock Quotes Exelixis|EXEL - Broker Consensus Forecast

- issuer market value details:

Market Capitalization Exelixis Inc.|EXEL - Total Enterprise Value

- issuer book value statistics:

Net Assets per Single Share Exelixis|EXEL - Company Book Value|Market Value to Book Value Ratio exelixis.com|EXEL - Company Assets

- debt and liquidity data:

- business earnings and investment ratios data:

EXEL - Company Net Income|Projected Future Earnings Exelixis, Inc.|EXEL - Market Cap to Net Income Ratio|Projected Price to Earnings Exelixis Corp|EXEL - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Exelixis Inc.|EXEL - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Exelixis|EXEL - Earnings per share for the last four quarters|Quarterly EPS earnings growth exelixis.com|EXEL - Earnings growth in current year|Net earnings per share growth forecast for next year Exelixis, Inc.

Analysis of all company metrics:EXEL (Exelixis)

Market capitalization measures the aggregate value of all shares, reflecting the current investor consensus regarding the business's future cash flows. Analyzing the market valuation history of Exelixis, Inc. (EXEL) reveals how the patent protection of Cabometyx and steady demand for oncology drugs convert into sustainable capital, ensuring high margins and shielding the asset's value from sharp market volatility.

Competitor analysis